Respiratory syncytial virus (RSV) is a common respiratory virus which disproportionally affects new-borns and infants.
Recently, Pfizer made public a $525 million acquisition of ReViral’s novel therapy for respiratory syncytial virus (RSV). Subsequently, there has been an increased interest in developing RSV therapies ...
Respiratory syncytial virus (RSV) is a major cause of infant hospitalization and a leading cause of death around the world for children under age 5. It's also a danger to older people. There are adult ...
Study shows key role for human T cells in the control of Respiratory Syncytial Virus (RSV) infection
A new study has shown that human T cells have an important role to play in controlling infection. Respiratory Syncytial Virus (RSV) is a highly contagious and seasonal respiratory virus that mainly ...
“It is a one-time injection of RSV antibodies. The antibodies last for about six months, so they protect babies through that ...
As several European countries are currently detecting respiratory syncytial virus (RSV) infections, ECDC issues rapid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback